The Outcome And Toxic Effect Of Treatment By Concurrent Chemoradiotherapy For Chinese Tibet Patients Of Locally Advanced Cervical Cancer

Purpose: To analysis the difference of outcome and toxic effect of for patients with Stage IIB-IVA cervical cancer in two different races;we carried out this retrospective study.Materials/Methods: A total of 168 locally advanced cervical cancer cases(Stage IIB-IVA)who received concurrent radiochemotherapy from July 2009 to July 2015 were enrolled and divided into two groups,the Chinese Han and Chinese Tibetan.Image-guided,Intensity-modulated Radiation Therapy(IG-IMRT)technology was adopted for external radiation in both groups;prescribed dosage was 1.8-2.0Gy/f*23-25 f for both groups.IMRT synchronized dosage compensation 3D-ICBT with high dosage rate was adopted for intracavitary therapy.Chemotherapy regimens for cisplatin plus paclitaxel double medicine scheme.Through the outpatient service,telephone communication for periodic review of the two groups of patients with follow-up survey,evaluation of two groups of patients' condition,the incidence of adverse reaction and outcome follow up.Acute or chronic toxicity evaluation reference the CTCAE V4.0 evaluation standard.Result: Survival analysis showed that the Tibetan and Han group three-year overall survival were 87.4% and 86.1% respectively(p > 0.05),and the three-year disease free survival were 81.2% and 83.7% respectively(p > 0.05),there were no significant statistical differences.Moreover,the Tibetan group has lower incidence of bone marrow suppression than the Han group(thrombocytopenia 42.3% vs 84.4%,P <0.001)and(decrease in hemoglobin77.2% vs 93.3%,P = 0.002).The Tibetan group has lower incidence of III–IV degree bone marrow suppression than the Han group(80% vs 65.40%,P = 0.033)and(12.8% vs 28.9%,P = 0.011),with statistical significance.No other incidence of acute and chronic toxicity difference were found between these two groups.Conclusion: For Chinese Han and Chinese Tibet patients of advanced cervical cancer;toxic effect of treatment by cisplatin plus paclitaxel regimen concurrent chemoradiotherapy was different but not outcome.Further randomized clinical study with longer follow up was needed to confirm our finding.